LegalView Informs Small Towns Surrounding A Closed Asbestos Mine of Mesothelioma Risks

(PRLEAP.COM) Denver, CO — LegalView alerted residents in the state of Vermont to reports that potential asbestos waste may be littered throughout the area surrounding a former asbestos mine. The mine was located in Lowell and Eden and now poses the threat of having had asbestos waste used in driveways and roadways throughout the surrounding towns and areas. Individuals who may have been exposed to asbestos fibers are encouraged to contact a mesothelioma lawyer who can provide information on the development of a potential mesothelioma lawsuit.

Once inhaled, the asbestos fibers and dust collect on the lining of the lungs and cause the development of cancerous cells, however, the condition remains dormant for years and potentially decades before a victim is aware of their condition and the mesothelioma symptoms accompanying their cancer. Contacting an experienced mesothelioma law firm may provide insight into litigation that can potentially offer a return of monetary compensation to pay for the extremely expensive medical bills associated with a mesothelioma diagnosis. LegalView offers information on the latest traumatic brain injury treatments as well as provides resources on the Avandia and Ketek prescription drug risks.

Approximately 5.4 million Americans currently suffer from a traumatic brain injury and this number only continues to rise, according to medical professionals and news reports that have deemed TBI the dominating injury of returning veterans from the Iraq war. However, while this number continues to rise, researchers also continue to study traumatic brain injury treatments to improve a TBI victim"s outcome. For information on these treatments visit LegalView, which offers a multitude of articles on TBI research and treatments.

LegalView also offers two informational portals on the controversial drugs, Ketek and Avandia. While both are prescribed for different reasons, each has increasingly made news headlines for alleged side effects causing severe damage to individual patients. Ketek is an upper respiratory antibiotic medication that treats common infections including community acquired pneumonia, bronchitis and streptococcus. It was approved for market by Sanofi-Aventis in April 2004 and, in 2006, a U.S. Food and Drug Administration (FDA) public safety advisory was issued on the drug regarding patients allegedly developing liver damage while consuming Ketek. Patients who may have experienced the Ketek side effects should contact a medical professional as well as the manufacturer regarding their potential condition.

Avandia is a type 2 diabetes medication from GlaxoSmithKline. It has recently made news headlines for risks related to early-onset osteoporosis as well as heart failure, according to a New England Journal of Medicine article from a June 2008 issue. Patients who are consuming Avandia for their diabetic and insulin needs may need to speak with their medical physician regarding a need for alternative medicines as well as a pharmaceutical attorney on the potential for an Avandia class action lawsuit.

About LegalView:

LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation’s most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com’s superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView.

Contact Information
Katie Kelley
LegalView.com
720-226-6613
Email LegalView.com

About This News Release

If you have any questions regarding information in these press releases please contact the organization listed in the press release. Issuers of press releases and not PR Leap are solely responsible for the accuracy of the content.

Share this News
PR Leap is a service of Condesa, Inc. © 2009 All Rights Reserved. Use of our service is governed by our Privacy Policy and Terms of Service.
Issuers of news releases are solely responsible for the accuracy of their content. Copyright / IP Policy